Results 61 to 70 of about 61,873 (295)

Tardive Dyskinesia and Dystonia – Clinical Case Review and Grand Rounds

Journal of Psychiatry Spectrum, 2022
Tardive dyskinesia (TD) syndromes are clinical conditions characterized by abnormal involuntary movements of the body and can range from occasional annoying involuntary movements to debilitating dystonia and are associated with increased mortality rates ...
Satish Suhas, Hariprasad Ganapathy Vijayakumar, Ganesan Venkatasubramanian, Shivarama Varambally   +3 more
doaj   +1 more source

Morphological Changes in Direct Pathway Striatal Neurons in a Rat Model of Tardive Dyskinesia

Movement Disorders, EarlyView.
Abstract Background Tardive dyskinesia (TD) and drug‐induced parkinsonism (DIP) arise from prolonged dopamine antagonist use. Although D2 receptor hypersensitivity in the indirect pathway is a proposed mechanism, the role of the direct pathway remains unclear.
Hiroki Hikichi, Haruo Nishijima, Fumiaki Mori, Iku Kinoshita, Chieko Suzuki, Koichi Wakabayashi, Masahiko Tomiyama   +6 more
wiley   +1 more source

D₂ Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways [PDF]

, 2005
Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of Gα GTPase accelerating proteins, is expressed specifically in the striatum, which participates in antipsychotic-induced tardive dyskinesia and in levodopa-induced dyskinesia. We
Axelrod, Jeffrey D., Barghshoon, Sami, Chen, Ching-Kang, Cheyette, Benjamin N. R., Ebert, Jana, Kovoor, Abraham, Lester, Henry A., Schwarz, Johannes, Schwarz, Sigrid, Seyffarth, Petra, Simon, Melvin I.   +10 more
core  

Valbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 1, March 2026.
Abstract Background Valbenazine is used to treat dyskinesia and is generally associated with limited side effects; however, a few cases with the adverse effect of parkinsonism are reported in the literature. In this study, we report a case of valbenazine‐induced acute parkinsonism.
Yasuhito Nagai, Miyata Mamiko, Koichi Miyakawa   +2 more
wiley   +1 more source

A case of tardive dyskinesia with paliperidone palmitate

Telangana Journal of Psychiatry, 2015
Background: Tardive dyskinesia is a neurological side effect of long term antipsychotics use. Incidence is common and found to be less prevalent with second generation antipsychotics than the first generation antipsychotics.
Philip Kumar Boyanapally, Nishanth Vemana, Phani Prasant Mulakaluri   +2 more
doaj   +1 more source

Effectiveness and safety of abobotulinumtoxinA in pediatric lower limb spasticity: A phase IV, prospective, observational, multicenter study

Developmental Medicine &Child Neurology, Volume 68, Issue 2, Page 227-239, February 2026.
Abstract Aim To assess the longitudinal attainment of patient‐centered, function‐related Goal Attainment Scaling Total (GAS T)‐score after repeated abobotulinumtoxinA (AboBoNT‐A) injections over a period of up to 30 months and up to 10 cycles. Method In this prospective observational study, the investigators' clinical practices recruited patients aged ...
Mark E. Gormley, Edward Dabrowski, Mauricio R. Delgado, Ann Tilton, Asare Christian, Sarah Helen Evans, Anne‐Sophie Grandoulier, Jumaah Goldberg   +7 more
wiley   +1 more source

Exploring Adjunctive Novel Therapeutic Approach of KarXT (Xanomeline‐Trospium Chloride) for Managing Psychotic Symptoms in Patients With Schizophrenia and Alzheimer's Disease

Brain and Behavior, Volume 16, Issue 1, January 2026.
An overview of the mechanism of action, clinical trials, and classical findings of KarXT for the management of psychotic symptoms in patients with schizophrenia and alzheimer's disease. ABSTRACT Background Acute psychotic symptoms like delusions and hallucinations are of major concern while treating patients with schizophrenia and alzheimer's psychosis,
Ashir Kanwal, Bismah Azeem, Hania Nasir, Fatima Mumtaz, Nauman Ashraf, Mohammed Hammad Jaber Amin, Warisha Kanwal, Bilal Wazir Khan   +7 more
wiley   +1 more source

A case of persistent tardive dyskinesia in bipolar mania

Psychiatry and Behavioral Sciences, 2013
Mr. CK, a 40-year-old Chinese gentleman is a Bipolar I Disorder patient with no history of depressive episodes. He had never achieved full remission and had 3 previous admissions for manic episodes due to poor insight to his illness.
Ong Kheng Yee
doaj   +1 more source

Comparison of Side Effects Between 3‐Monthly and 1‐Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia

Human Psychopharmacology: Clinical and Experimental, Volume 41, Issue 1, January 2026.
ABSTRACT Background The paliperidone palmitate 3‐month (PP3M) formulation offers an extended dosing interval compared to the 1‐month (PP1M) formulation. However, data on the comparative side effect profiles of PP1M versus PP3M in real‐world settings remain limited.
Erkan Kuru, Ilker Ozdemir, Bengu Yucens, M. Hakan Türkçapar   +3 more
wiley   +1 more source

Trihexyphenidyl triggered hypomania in a bipolar patient

Psychiatry and Behavioral Sciences, 2012
We observed a case of tardive dyskinesia after regular use of low dose chlorpromazine. An anticholinergic agent; trihexyphenidyl (THX) was used to treat the tardive dyskinesia.
Eren Yıldızhan, Serap Batmaz, Nazan Karagoz Sakallı, Erhan Kurt   +3 more
doaj   +1 more source